Short CV/Education and training

  • Since 2019
    Full professor in Immunology, head of the department of Tumor Immunology at the Radboud Institute for Molecular Life Sciences (Currently supervising 8 technicians, 17 AGIKOs/PhD students, 3 post-docs.), Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

  • 2011 – 2019
    Professor Translational Tumor Immunology, Department of Tumor Immunology 0.75 fte and Medical Oncology 0.25 fte, Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

  • 2009 – 2011
    Senior lecturer, Department of Tumor Immunology 0.75 fte and Medical Oncology 0.25 fte, Nijmegen Centre for Molecular Life Sciences (Supervision 8 technicians, 4 AGIKOs/PhD students, 4 post-docs.), Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

  • 2004 – 2009
    Staff member Department of Tumor Immunology, 0.5 fte tenured; Department of Pediatric Hemato-oncology 0.5 fte fixed term, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. Supervision 6 technicians, 4 AGIKOs/PhD students, 4 post-docs.

  • 1997 – 2004
    Post-doc, 1 fte, fixed term, Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. Supervision 2-4 technicians, 2-3 AGIKOs/PhD students, 2-3 post-docs.

  • 1993 – 1994
    Visiting Scientist, Department of Hematology, University Hospital Zurich, Zurich, Switzerland.

  • 1991 – 1997
    PhD project, 1 fte, fixed term, Department of Dermatology, University Medical Center Utrecht, The Netherlands. Supervision 1 technician.

  • 1990 – 1991
    Researcher, 1 fte, tenured term, Swiss Institute for Allergy and Asthma research, Davos, Switzerland

Selected publications

  • Tel J, Schreibelt G, Sittig SP, Mathan TS, Buschow SI, Cruz LJ, Lambeck AJ, Figdor CG, de Vries IJ. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood, 2013. 121(3): 459-67.

  • Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? The lancet oncology, 2012. 13(1): e32-42.

  • Schreibelt G, Klinkenberg LJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, Adema GJ, Brown GD, Figdor CG, de Vries IJ. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood, 2012. 119(10): 2284-92.

  • Tel J, Smits EL, Anguille S, Joshi RN, Figdor CG, de Vries IJ. Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood, 2012. 120(19): 3936-44.

  • Lesterhuis WJ, Punt CJ, Hato SV, Eleveld-Trancikova D, Jansen BJ, Nierkens S, Schreibelt G, de Boer A, Van Herpen CM, Kaanders JH, van Krieken JH, Adema GJ, Figdor CG, de Vries IJ. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. The Journal of clinical investigation, 2011. 121(8): 3100-8.

  • Schreibelt G, Benitez-Ribas D, Schuurhuis D, Lambeck AJ, van Hout-Kuijer M, Schaft N, Punt CJ, Figdor CG, Adema GJ, de Vries IJ. Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood, 2010. 116(4): 564-74.

  • Srinivas M, Aarntzen EH, Bulte JW, Oyen WJ, Heerschap A, de Vries IJ, Figdor CG. Imaging of cellular therapies. Adv Drug Deliv Rev, 2010. 62(11): 1080-93.

  • Meyer-Wentrup F, Benitez-Ribas D, Tacken PJ, Punt CJ, Figdor CG, de Vries IJ, Adema GJ. Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood, 2008. 111(8): 4245-53.

  • Benitez-Ribas D, Adema GJ, Winkels G, Klasen IS, Punt CJ, Figdor CG, de Vries IJ. Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4+ T cells after Fc gamma RII-mediated uptake. J Exp Med, 2006. 203(7): 1629-35.

  • Tacken PJ, de Vries IJ, Gijzen K, Joosten B, Wu D, Rother RP, Faas SJ, Punt CJ, Torensma R, Adema GJ, Figdor CG. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood, 2005. 106(4): 1278-85.


Selected projects

  • TDAR-on-a-chip: a human in vitro HTS TDAR assay platform. Crack-it Challenge. Principal Investigator: IJM de Vries, Mimetas, ImmunXperts

  • Effects of Human Milk Oligosaccharides in infant and adult nutrition and immune health. Health Holland, Friesland Campina. Principal Investigator: IJM de Vries, V Triantis HH Nutricia

  • tolDC therapy for rheumatoid arthritis. Principal Inverstigator: ZonMW, SGF, Health Holland consortium, IJM de Vries

  • Optimizing the design of dendritic cell vaccine immunotherapies. ZonMW. Principal Investigator: IJM de Vries, G. vd Bogaart, S. van Kasteren

  • KIKA 359: Dendritic cell vaccines to prevent cancer in Constitutional Mismatch Repair Deficiency (CMMR-D) syndrome. Principal Investigator: G Schreibelt, MCJ Jongmans, IJM de Vries, N Hoogerbrugge

  • KWF 12413: Induction of neo-antigen specific T cells by specialized cross-presenting dendritic cells in epithelial ovarian cancer patients. Principal Investigator: IJM de Vries, PB Ottevanger

  • ONCOBIOME, Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response. H2020-SC1-2018-825410. Principal Investigator: EU consortium, IJM de Vries

  • KWF 11618: Galectin-9 is required for dendritic cell function during anti-melanoma immunity. Principal Investigator: IJM de Vries, AB van Spriel

  • DC4Balance, Dendritic Cell Targeting for Resetting Immune Balance. Health-Holland, Top Sector Life Sciences & Health. Principal Investigator: Consortium, IJM de Vries

  • KWF 10673: Towards prediction of the outcome of cancer immunotherapy. Principal Investigator: CG Figdor, IJM de Vries

  • PRECIOUS, Scaling-up immunomodulating nanomedicines for multimodal precision cancer immunotherapy EU H2020 (coordinator)

  • NWO-ZonMw 2016, Vaccinaties met autologe, natuurlijk circulerende dendritische cellen (nDC) beladen met synthetische peptides bij patiënten met maligne melanoom stadium IIIb en IIIc: evaluatie van klinische respons, kwaliteit van leven en economische aspecten. Principal Investigator: IJM de Vries

  • Dendritic cell therapy part of the Dutch Health Care system (Voorwaardelijke toelating basispakket), to carry out a large randomized study with natural dendritic cell vaccines.

  • PROCROP, Professional cross-priming dendritic cells for ovary and prostate cancer H2020-PHC-2014-two-stage- 635122. Principal Investigator: EU consortium, IJM de Vries

  • ATK, Stichting afweer tegen kanker: Natural dendritic cells for immunotherapy of chemo-naive metastatic castration-resistant prostate cancer patients. Principal Investigator: IJM de Vries, H. Westdorp, F Witjes, W Gerritsen

  • KWF 2013-6430: GMP production of PLGA beads for in vivo cell tracking. Principal Investigator: IJM de Vries, ML Zandvliet, CG Figdor

  • NWO Vici: Theranostics for the development of successful natural dendritic cell vaccines to combat and prevent cancer. Principal Investigator: IJM de Vries

  • Radboudumc JO project 2013: Multifunctional Fight against Cancer. Supervisors: IJM de Vries, J Jacobs

  • Swedish Research Society 2013: Dissecting mechanisms exploited by plasmacytoid dendritic cells for antitumor immunity in therapeutically vaccinated prostate cancer patients. Supervisors: IJM de Vries, R. Kiessling

  • RIO JO project 2013: Dissecting mechanisms exploited by plasmacytoid dendritic cells for antitumor immunity in prostate cancer patients. Principal Investigator: IJM de Vries, W. Gerritsen

  • NWO-ZonMW 2012:pTO 95103002: Natural circulating plasmacytoid dendritic cells: Key for antitumor immunity? Principal Investigator: IJM de Vries

  • BetaTrain: European Training Network for Excellence in Molecular Imaging in Diabetes, EC FP7 ITN.

  • KWF 2010-4722: Vaccination of early-stage high-risk uveal melanoma patients with mRNA-transfected dendritic cells. Principal investigators: IJM de Vries, CJA Punt, ADA Paridaens.

  • KWF 2006-3699: Toll like receptor-mediated dendritic cell maturation: The key towards induction of potent anti-tumor immunity? Principal investigators: IJM de Vries, GJ Adema, CJA Punt.

  • NWO Vidi: Dendritic Cells en route. Principal investigator: IJM de Vries.

  • NWO Aspasia. Principal investigator: IJM de Vries.

  • ENCITE, European Network for Cell Imaging and Tracking Expertise, EC FP7 project.

  • Pharmachild, Long-term PHARMacovigilance for adverse effects in childhood arthritis focusing on immune modulatory drugs, EC FP7 project.

  • NWO-ZonMW 2008: pTO 95100106: Boosting the immune response to prevent cancer: Frameshift neopeptide-derived antigens as novel tumor specific targets for immune therapy in hereditary colorectal cancer. Principal investigators: IJM de Vries, N. Hoogerbrugge.

  • KWF 2009-4580: NPK project translational research.

  • Van der Es foundation 222, 2010: STAT6 en platinum-chemotherapie gevoeligheid. Principal investigators: WJ Lesterhuis, CJA Punt, IJM de Vries.

Patents

  • Composition and methods for generating an immune response in a subject

  • Peptides for use in the immunotherapy of renal cell carcinoma

Membership in scientific bodies/juries

  • Elected research member of the Academia Europaea (2021-present)

  • Elected council member of the International Union of Immunological Societies (IUIS)(2020-present)

  • European Society of Molecular Imaging, TOPIM 2020 committee member

  • President NVVI – Dutch Society for Immunology (2018-present)

  • European Society of Molecular Imaging (ESMI) elected board member (2018-present)

  • European Society of Molecular Imaging, fouding member and chair of Immune Oncology & Therapy study Group (2017-2020)

  • Ambassador Board topX – a unique platform for women in Life Science (2020- present)

  • Member Research Council Panel Norway (2018, 2019, 2020)

  • Panel member in the domain of Biomedical Sciences of the Free University Brussels (VUB) Strategic Research Programs

  • Panel Member in the evaluation of the 2016 ERC consolidator grants (2016)

  • Elected member of the European Academy for Tumor Immunology (EATI) (since 2016)

  • Chair of the Scientific Evaluation Committee of “The ERA-NET TRANSCAN-2” (European Research Area Network: Aligning national/regional translational cancer research programmes and activities) Joint Transnational Call for proposals (15 funding organisations from 11 countries) (2015-2016)

  • Member of the program committee & poster discussant at ESMO Symposium on Immuno-Oncology (2015)

  • Organizer of the European Molecular Imaging meeting of the European Society for Molecular Imaging (2015)

  • Project advisor 1Valve (2014)

  • Board member of patient organization Patientenstem.nu (2015-present)

  • Board member of patient organization Inspire2Live (2014-2015), since 2015 scientific advisor

  • Member of the program committee of the yearly NVVI Wintermeeting (1/2014- present)

  • Member of the translational and applied research council of the Dutch Cancer Foundation (2013- 2019)

  • Member of the educational taskforce “Revision of the curriculum for the bachelor degree in biomedical sciences in Nijmegen” (2013-2014)

  • Member of the user committee (gebruikerscommissie) of project 95103005 entitled " Minor H antigen UTA2-1-loaded DC dendritic cells (DC)as vaccines to improve the therapeutic effect of donor lymphocyte infusions in B cell malignancies" PI Tuna Mutis, UMC Utrecht (2013-2015)

  • Organizer of ENCITE workshops ‘ Imagine Cancer: from Models to Patients’, Nijmegen (the Netherlands), 1/2012

  • Member of the training and supervision plan committee of the clinical institutes of RUN-MC

  • Member of the management team NCMLS, since 01/2011

  • Organizer of the 2010 edition of the Dutch Tumor Immunology Meeting (Breukelen, The Netherlands, 06/2011)

  • Organizer of the 2010 edition of the Dutch Tumor Immunology Meeting (Breukelen, The Netherlands, 06/2010)

  • Site visit of the research cancer center headed by Jean Jacques Fournié in Toulouse (France). On behalf of the French National Agency for Research Evaluation (AERES), November 19-20, 2009

  • Application for CCMO permission to perform clinical trials

  • Organizer of the 2009 edition of the Dutch Tumor Immunology Meeting (Breukelen, The Netherlands, 06/2009)

  • Co-organizer of N4I science day 2009, 2010,2011

  • Member of the NCMLS seminar committee, 11/2009 – 5/2011

  • Organizer of the 2008 edition of the Dutch Tumor Immunology Meeting (Breukelen, The Netherlands, 06/2008)

  • Co-organizer of the conference DC2003 (Amsterdam, The Netherlands)

Contact

You can only see the contact information of the academics in the database if you are a registered user of AcademiaNet.
Please register here

Testimonials

  1. Read what our members say about AcademiaNet.

Follow us

Similar profiles

  1. Prof. Anne Angelillo-Scherrer

    Biological and related sciences, Health, Hematology, Internal Medicine; Special focus: hemostasis and thrombosis, laboratory diagnosis particularly in the field of hemostasis and thrombosis, myeloproliferative neoplasms and their bleeding/thrombotic complications

  2. Dr. Irene Agyepong

    Health, Public Health

  3. Dr. Ana Allende

    Agriculture, Health, Food Safety

  4. Prof. Dr. Katrin Amunts

    Health, Brain research

 
 
Academia Net